
N8 Medical Inc Profile last edited on: 10/8/2019
CAGE: 6XCD3
UEI: ZE5AN7PM3N39
Business Identifier: Antimicrobial surface-protected medical devices: reduction of infection and related complications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 12
County: Franklin
Congr. District: 12
County: Franklin
Public Profile
N8 Medical, LLC (N8 Medical) is a clinical-stage medical device company structured around development of medical devices that incorporate a novel class of active (proprietary) compounds called ceragenins - synthetic, non-peptide small molecule mimetics of endogenous host defense peptides. The public health and economic burden associated with device-related infections and other complications associated with medical devices factors to multi-billions of dollars. The proprietary ceragenin compounds utilized by N8 Medical - engaging the firm's CeraShiled (TM) technology - can impart unique properties to medical devices to include antimicrobial, anti-inflammatory and other therapeutic properties representing both a major business development opportuity and an important health benefit both in terms of improved patient outcomes and a likely lowering of theoverall cost of care. In Spring 2019, N8 announced the First-in-Human Use of its CeraShield Endotracheal Tube
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $2,195,642 | |
Project Title: A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices | ||||
2023 | 1 | NIH | $258,455 | |
Project Title: Ceragenin-coated pedicle screws to tackle surgical-site infections | ||||
2022 | 1 | NIH | $299,155 | |
Project Title: Ceragenin-based antimicrobial coating to tackle hemodialysis catheter-related infections |
Key People / Management
Ronald Bracken -- President and Chief Operating Officer
Marc Rohman -- Chief Executive Officer
Glenn Brunner -- VP, Product Development
Carl Genberg -- Founder, Chief Scientific Officer Senior VP, R&D,
Marc Rohman -- Chief Executive Officer
Glenn Brunner -- VP, Product Development
Carl Genberg -- Founder, Chief Scientific Officer Senior VP, R&D,